A detailed history of First National Trust CO transactions in Annovis Bio, Inc. stock. As of the latest transaction made, First National Trust CO holds 15,000 shares of ANVS stock, worth $22,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,000
Holding current value
$22,200
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 08, 2025

BUY
$1.5 - $5.39 $22,500 - $80,850
15,000 New
15,000 $22,000

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $12.1M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track First National Trust CO Portfolio

Follow First National Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First National Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on First National Trust CO with notifications on news.